SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy
Colorectal Cancer
RADIATION: SCRT|DRUG: Camrelizumab|DRUG: Fluzoparib|DRUG: CAPEOX
Adverse events, Incidence and grade according to NCI-CTCAE 5.0(including serious adverse events and immune-related adverse events); Surgical safety: surgical complications, 30 - and 90-day postoperative mortality, length of stay, and reoperation rate, up to 36 months|pCR (Pathological Complete Response), The proportion of subjects with no residual viable tumor cells(ypT0N0) in the primary tumor and lymph nodes, also defined as the proportion of subjects with grade 0 in the AJCC Tumor Regression Grading (TRG) scoring system(version 8.0)., up to 6 months
3-year Event-Free Survival(EFS) rate, The percentage of patients without disease recurrence or progression or death due to any cause after 3-year follow-up, up to 36 months|Overall Survival(OS), The time from the date of randomization to the death caused by any cause, up to 36 months|R0 resection rate, The rate of negative margin microscopically, up to 6 months|Completion rate of neoadjuvant therapy, the rate of NAT completion, up to 6 months|Tumor Regression grade (TRG), Evaluated according to AJCC Version 8 TRG scoring system, up to 6 months|quality of life (QOL), The EORTC QLQ-C30 scale was used, up to 36 months
biomark, evaluate the relationship between potential biomarkers (including but not limited to MMR status, PD-L1 expression) and efficacy, up to 36 months
To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy